2,220 Hits in 12.8 sec

Open Data for Research and Strategic Monitoring in the Pharmaceutical and Biotech Industry

Baldissera Giovani
2017 Data Science Journal  
The information collected provides a snapshot of the use of open data by the pharmaceutical and biotech industry in 2015-2016.  ...  The companies interviewed use open data to complement proprietary data for research purposes, to implement licensing-in/licensing-out strategies, to map partnerships and connections among players or to  ...  Acknowledgements This work would not have been possible without all the people that have offered their time to answer to the survey.  ... 
doi:10.5334/dsj-2017-018 fatcat:7dmb47xqibg57i6ac5obiwrczy

The interplay between new technology based firms, strategic alliances and open innovation, within a regional systems of innovation context. The case of the biotechnology cluster in Belgium

Jean-Pierre Segers
2015 Journal of Global Entrepreneurship Research  
In future research, the impacts of open innovation and novel business models warrant further attention.  ...  Strategic partnerships in the biotechnology industry allow new technology based firms to gain a foothold in this high-cost, high-risk industry.  ...  For this research, a sample of stock-exchange-listed biotechnology firms in Belgium are screened and monitored.  ... 
doi:10.1186/s40497-015-0034-7 fatcat:xski6jnderenzhatcgku3mapne

Small-Firm Strategic Research Partnerships: The Case of Biotechnology

David Audretsch, Maryann Feldman
2003 Technology Analysis & Strategic Management  
We begin by examining the alliance strategy for knowledge-based small firms in general and then turn our attention to the case of biotech.  ...  A This paper provides an overview of the theoretical motivation and the empirical literature on small firm strategic alliances in biotechnology, an industry where these alliances have proliferated  ...  Acknowledgements The authors wish to thank Frank Baldwin for research assistance and Merry Perry for editorial assistance, and Al Link and other workshop participants for their comments and suggestions  ... 
doi:10.1080/0953732032000051154 fatcat:wsq2xqsf6bgxfnrneu2rtcdqse

R&D management in the pharma industry: the strategic role of CROs

2018 Sinergie Italian Journal of Management  
Research limitations: Further investigation will be useful to understand emerging business models in Italy and in other national innovation systems and to appreciate the changing role of CROs in the strategic  ...  Research and managerial implications: Results could indicate CRO's next step towards so-called "virtual model", to meet the expectations of the most dynamic open innovation approaches in PI.  ...  The data analysis showed that the observed CROs in Italy are slowly changing their strategic perspectives and strive for an open model, in particular by shifting the outsourcing model from a transactional  ... 
doi:10.7433/s101.2016.03 fatcat:diptad776raa5ajoug44nkjv4a

Innovation in the Pharmaceutical Industry: The Process of Drug Discovery and Development [chapter]

Elina Petrova
2013 International Series in Quantitative Marketing  
We discuss the evolving organizational forms and models for collaboration, summarize signifi cant empirical regularities, and highlight differences in market positions related to fi rms' strategic orientation  ...  As a guide to future research, critical drivers and modes for drug innovation are systematized in a unifying framework of characteristics and process decisions, and multiple areas in need of further scrutiny  ...  Fig. 2.1 The research and development process for new drugs (compiled from data in PhRMA Pharmaceutical Industry Profi le 2011 ; DiMasi and Grabowski 2007 ) 71-84%~ 11% 5% 35% 15% 8% 25% of Total  ... 
doi:10.1007/978-1-4614-7801-0_2 fatcat:uc4v5f5qfbfw5p4rglkgrxo6li

Strategic Partnerships and Open Innovation in the Biotechnology Industry in Belgium

Jean-Pierre Segers
2013 Technology Innovation Management Review  
For this research, a number of stock-exchange-listed biotechnology firms in Belgium are screened and monitored.  ...  The first section provides an overview of biotechnology business models to show how strategic partnerships and open innovation are commonly leveraged in this industry.  ...  Keywords: strategic partnerships, biotechnology, Belgium, open innovation, business models, R&D Strategic Partnerships and Open Innovation in the Biotechnology Industry in Belgium Jean-Pierre Segers  ... 
doi:10.22215/timreview676 fatcat:lb2gddewo5a2lpkeyt6xa5455u

Drug discovery in pharmaceutical industry: productivity challenges and trends

Ish Khanna
2012 Drug Discovery Today  
The partners have open access to the data, technology and training options to utilize in their own research or proprietary projects.  ...  . open access IBM used pharmaceutical data from BMS, AstraZeneca, DuPont, Pfizer Data extracted from 2.4 million compounds, 4.7 million patents and 11 million biomedical journals Researchers at the  ... 
doi:10.1016/j.drudis.2012.05.007 pmid:22627006 fatcat:f222judfqfgiffbxcxwk7cw2ve

Pharmaceutical R&D Productivity: The Role of Alliance

Sarah Kruse, Mark Slomiany, Rema Bitar, Sarah Jeffers, Mahmud Hassan
2014 Journal of Commercial Biotechnology  
In this paper, we highlight a number of the major alliances reshaping the industry and the role of government, research institutions, and other players in the public-private interface in these endeavors  ...  With long-term research divisions shed in favor of short-term outsourcing options and with public good will at historic lows, industry innovators have sought to reinvent the model of big pharma, its relationship  ...  BIotech Partners In BusIness develoPment The pharmaceutical industry has long capitalized on the technology and expertise of biotech companies in early drug development.  ... 
doi:10.5912/jcb632 fatcat:w7xe5re7rrblrbekr7tweoqlk4

Exploring management issues of cross-border R&D alliances in the Australian biotechnology industry

Adnan Syed Muhammad
2013 Innovation and Development  
For example in the pharmaceutical industry, firms can make strategic alliances to speed up the process of research, development and commercialisation of new drugs and become the first mover in the market  ...  McCutchen and Swamidass (2004) studied motivations for strategic alliances in the pharmaceutical and biotechnology industry and found that the motivations in this industry changed with time: they found  ...  Candidate of the Centre for Industry and Innovation Studies Research Group within the University of Western Sydney.  ... 
doi:10.1080/2157930x.2013.833774 fatcat:cwc7qogll5f7bmvrifhnxcidh4

Who is interested in biotech? R&D strategies, knowledge base and market sales of Indian biopharmaceutical firms

Shyama V Ramani
2002 Research Policy  
This paper addresses three main questions on Indian pharmaceutical firms that have integrated biotechnology in their marketing, production or research activities: (i) What kind of labour stocks of the  ...  (ii) Which components of the R&D strategy are strategic substitutes and which are strategic complements?  ...  Acknowledgements I gratefully acknowledge financial assistance from INRA under the programme "Theory of Contracts" that made the research for this paper possible.  ... 
doi:10.1016/s0048-7333(01)00115-9 fatcat:thblmdkw7bfnpczctityy4keka

Innovative strategy for the pharma of the future: summary of trends and projections 2017-2018

Irina I Agoulnik
2018 Journal of Analytical & Pharmaceutical Research  
In this review we summarized twenty-four reports, articles, and posts with projections and trends in pharmaceutical industry for years 2017 and 2018.  ...  The focus of this review is on two major requirements for the Pharmaceutical industry of the future: innovative corporate strategy, and technology strategy.  ...  Louise Bergeron, VP of Biology at Encycle Therapeutics, Canada, for inspiration and valuable insights about the drug development industry.  ... 
doi:10.15406/japlr.2018.07.00212 fatcat:ccf2ckje6fcbzftp7e6oiescwq

Biotechnology in Catalonia; Industry Analysis

Nuria Mas
2009 Social Science Research Network  
However, Catalan biotech is still quite small in relation to the top European bioclusters and it is only slowly catching up in some of its strategic components.  ...  The main challenge it faces is access to funding and the fact that the size of related industries in the area is smaller than their size in the top European biotech regions.  ...  Scientific Production and Quality Basic scientific research has a strategic importance for the future survival of the Catalan biotechnology sector.  ... 
doi:10.2139/ssrn.1482994 fatcat:mdug3mbl6vbnvhr6qyejtmth6y

The increasing role of contract research organizations in the evolution of the biopharmaceutical industry

Balconi Margherita, Lorenzi Valeria
2017 African Journal of Business Management  
and underlining the consequences of their growth for the effective functioning of the whole industry.  ...  The role played by contract research organizations (CROs) in the last decades has been almost completely neglected by the economic and managerial literature, which at most presents an outdated and misleading  ...  In the absence of official data, the importance of this segment of the industry is brought to light only by some analysis and discussions in the medical literature and some managerial contributions mainly  ... 
doi:10.5897/ajbm2017.8360 fatcat:lwurdamyabbrlbt7xi2qjc6qqm

Patient‐driven search for rare disease therapies: the Fondazione Telethon success story and the strategy leading to Strimvelis

Lucia Monaco, Lucia Faccio
2017 EMBO Molecular Medicine  
Conflict of interest The authors declare that they have no conflict of interest.  ...  transfer activities that enable strategic partnerships with biotech companies and pharmaceutical industries.  ...  partnerships with pharmaceutical and biotech companies.  ... 
doi:10.15252/emmm.201607293 pmid:28148554 pmcid:PMC5331198 fatcat:b7hor75y5vdvlkrsibv57vofja

Institutional embeddedness and the strategic leeway of actors: the case of the German therapeutical biotech industry

K. Lange
2008 Socio-Economic Review  
In order to evaluate this question, we focus on the therapeutic biotech industry and draw a German-British comparison.  ...  Our empirical findings show that British firms are indeed more competitive in the therapeutical biotech industry, but only to a limited extent.  ...  Acknowledgements This paper draws on findings from the PhD research project I carried out between 2002 and 2005 at the Max Planck Institute for the Study of Societies (Cologne).  ... 
doi:10.1093/ser/mwn029 fatcat:6wgdkry4ifdntowocbeb4zyoom
« Previous Showing results 1 — 15 out of 2,220 results